SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel $INTC is trending as chatter swirls around a potential investment from Apple $AAPL as part of Intel's turnaround efforts, fueled by a recent Bloomberg report. Community members are speculating about the implications of Apple taking a stake and potential collaborations, while some express skepticism, recalling past struggles. The news arrives amid broader discussions of government support for US chip manufacturing and Intel's role in the AI landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a surge in investor interest, fueled by a recent Air Force contract and non-dilutive funding, which validates the company's quantum computing roadmap. The community is actively discussing the stock's potential, comparing it to other high-growth tech stocks and debating whether it's overvalued. Some traders are pointing to a potential short squeeze, while others highlight the long-term potential of quantum computing and the company's partnerships.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending following positive Phase I/II data for its Huntington's disease gene therapy, with analysts raising price targets and the community discussing its potential for accelerated FDA approval. Bullish sentiment is fueled by the statistically significant slowing of disease progression, while some traders are wary of a potential offering or pullback. The stock's high short interest is adding to the volatility as traders debate whether to short the stock or ride the momentum.

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

TNF Pharmaceuticals Inc.

TNF Pharmaceuticals (TNFA) is trending as traders discuss its recent strategic shift towards quantum computing and a name change to Q/C Technologies, sparking both excitement and skepticism. Bullish sentiment centers on the potential of their exclusive rights to light-speed laser processing for cryptocurrency applications, while bears cite concerns about dilution and the company's history. The community is actively debating whether this pivot justifies the stock's increased volatility and potential for a short squeeze.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending due to reports of the Trump administration potentially taking an equity stake in the company linked to a $2.26 billion Energy Department loan, sparking significant community discussion around potential government backing and the future of lithium supply. The news has triggered a surge in the stock price as investors speculate on the implications for the company's Thacker Pass project and the broader lithium sector, with some comparing it to previous government investments in critical industries. Discussions also include potential dilution and off-take agreements.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is trending due to a significant sell-off, with community members citing potential Intel/Nvidia competition and overvaluation concerns as possible catalysts; some suspect market manipulation. Despite strong YTD growth fueled by PCIe demand and a recent positive earnings report, investors are debating its sustainability amid competition from major players like AVGO and MRVL. Discussions include whether the drop is a buying opportunity or a sign of further declines.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation about a potential buyout or partnership, especially with other companies in the weight loss space being acquired. Community members are actively discussing potential suitors and the value of Viking's pipeline, citing positive trial data and a manageable tolerability profile. Some traders are eyeing technical indicators, while others are focused on upcoming presentations and potential catalysts.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending due to positive survival data in its Phase 2a trial for pancreatic cancer treatment, sparking community interest and analyst upgrades. However, a proposed public offering is creating mixed sentiment, with some fearing dilution while others see it as a strategic move. The community is actively discussing the balance between the promising data and the potential impact of the offering on the stock's future.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid debates about its valuation and future prospects, with discussions focusing on its lack of current revenue and potential for an offering. Community sentiment is divided, with some highlighting insider selling and regulatory hurdles, while others point to the company's potential role in powering AI data centers. The stock's significant gains over the past month have also spurred conversations around pullbacks and potential buying opportunities within the nuclear sector.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as the community discusses its recent price movement and potential breakout above the $15-$16 resistance level, with some pointing to a shift in market sentiment. The groundbreaking of the Georgia plant is also generating buzz, although some express concerns about cash burn and production timelines. Overall, the conversation is focused on whether Rivian can maintain its upward momentum and capitalize on upcoming catalysts like the R2 launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.

All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy

Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?

Shares of Mind Medicine Inc. climbed 3.6% on Thursday and extended gains after hours, with retail sentiment improving following the company's fourth-quarter earnings report.The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier, largely due to higher research and development costs tied to its MM120 and MM402 programs.&nbsp;MM120, MindMed's lead drug candidate, is designed to treat generalized anxiety disorder (GAD), while MM402 is being developed to address core symptoms of Autism Spectrum Disorder (ASD).However, the company's adjusted Q4 loss per share of $0.41 narrowed from $0.59 a year ago, though it missed analyst expectations of a $0.28 loss.CEO Rob Barrow remained upbeat, stating that 2024 was a "year of significant progress" and that the company had achieved key milestones leading into multiple Phase 3 clinical readouts for MM120, which he expects to drive MindMed's next growth phase.On Stocktwits, sentiment for MNMD shifted from 'bearish' to 'neutral' in the 24 hours leading up to Thursday, with message volume surging 250%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_as_of_March_6_8b8a5ebcbf.png" alt="MNMD sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>MNMD sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user expressed confidence in MM120's potential, saying, "Once Phase 3 [of the MM120 study] passes, this is going to blow up."<stembedurl>https://stocktwits.com/Bball4/message/606995440</stembedurl>Another key factor boosting optimism was MindMed's strong cash reserves. The company ended 2024 with $273.7 million in cash and cash equivalents, up from $99.7 million a year earlier, which the company expects to be sufficient to support operations into 2027.One user wrote, "We won't have to do any more reverse splits. MNMD has cash reserves until approvals."<stembedurl>https://stocktwits.com/BullsVSBearsVSYoMomma/message/607108323</stembedurl>Additionally, traders pointed to potential government&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-soars-after-rfk-jr-confirmed-as-hhs-chief/ch5iJvpRH6">support</a> under new Health and Human Services chief Robert F. Kennedy Jr., who has previously advocated for the decriminalization of psychedelics for therapeutic use.The company also plans regulatory and pre-commercialization activities for MM120's orally disintegrating tablet (ODT) version.One watcher pointed out that although MNMD lags behind competitor Compass Pathways in clinical progress, its broader drug pipeline gives it an edge.Mind Medicine shares remain down over 7% year-to-date but have gained over 10% in the past 12 months.&nbsp;According to Koyfin, of the 11 analysts covering the stock, seven rate it a 'buy,' while four have a 'strong buy' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Equity

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.


MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, as retail traders cheered Robert F. Kennedy Jr.’s confirmation as U.S. Health and Human Services secretary.The stock is now set to post weekly gains of over 22%, its strongest performance since the week of Donald Trump’s 2024 election victory in November.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_Feb_14_dada4484f8.png" alt="MNMD sentiment Feb 14.png" width="1318" height="324"><figcaption>MNMD sentiment Feb 14 as of 2:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment turned even more bullish, with message volume skyrocketing 720% in the past three months amid RFK Jr.’s rise to the cabinet.“The RFK bump,” one user wrote, echoing several other posts, while another predicted a “big breakout” next week.&nbsp;<stembedurl>https://stocktwits.com/mpferd/message/604362153</stembedurl><stembedurl>https://stocktwits.com/Knot2/message/604306853</stembedurl>Kennedy has previously&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/livecoverage/trump-cabinet-confirmation-hearings/card/what-has-rfk-jr-said-about-weight-loss-drugs-antidepressants-and-psychedelics--eAaDAxA6vQaSVMeBPlEs">advocated</a> for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.Wall Street has also taken notice.&nbsp;Earlier this month, Chardan named Mind Medicine as a top biotech pick for 2025, citing strong Phase 2 results for its lead drug candidate MM120, which targets generalized anxiety disorder (GAD).&nbsp;The research firm has a ‘Buy’ rating with a $20 price target — implying a doubling from current levels — and projects potential MM120 peak sales of over $1 billion by 2026.In January, Evercore ISI <a href="https://stocktwits.com/news-articles/markets/equity/mnmd-stock-rises-on-evercore-isi-rating/chbVQU4RYM">initiated</a> coverage with an ‘Outperform’ rating and a $23 target, highlighting Mind Medicine’s innovative oral LSD formulation and its potential in treating both GAD and major depressive disorder (MDD).Still, not everyone’s betting on more gains. Short interest has climbed from 12.9% at the start of the year to 14.2% by January’s end, per Koyfin data.<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine shares</a> have gained over 42% year-to-date, outperforming Compass Pathways but lagging Atai Life Sciences’ 79% surge. Those two companies are also developing psychedelic therapeutics.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Robert F. Kennedy Jr. speaks after being sworn in as Secretary of Health and Human Services in the Oval Office at the White House on February 13, 2025 in Washington, DC. (Photo by Andrew Harnik/Getty Images)

Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months

Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that...

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

Shares of Mind Medicine Inc. climbed over 2% on Tuesday afternoon, on track to break a two-session losing streak, as Evercore ISI initiated coverage with an&nbsp;‘Outperform’&nbsp;rating and a bullish $23 price target, suggesting over 200% upside from current levels.Evercore analysts highlighted the company’s innovation in developing a novel oral formulation of LSD, with its lead asset MM120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD).&nbsp;The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.Last month, Chardan initiated coverage with a&nbsp;‘Buy’ rating and a $20 price target, citing MM120’s potential to deliver over $1 billion in peak sales by 2026, assuming positive trial data and a strong commercial launch.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MNMD_sentiment_and_message_volume_Jan_28_9a6374b37a.png" alt="MNMD sentiment and message volume Jan 28.png" width="1318" height="324"><figcaption>MNMD sentiment and message volume Jan 28 as of 12:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for Mind Medicine turned ‘bullish’ from ‘neutral,’ with increased message volume reflecting optimism.&nbsp;<stembedurl>https://stocktwits.com/EMT6/message/601825856</stembedurl><stembedurl>https://stocktwits.com/MichaelNaussCMT/message/601770767</stembedurl>Analysts expect sentiment to improve further in 2025, as the company nears key catalysts, including pivotal trial updates.Mind Medicine recently launched a Phase 3 trial of MM120 in GAD and expanded its intellectual property protection through 2041 by obtaining a patent for an orally disintegrating tablet (ODT) formulation.&nbsp;The Nasdaq Biotechnology Index (NBI) added the stock in December, which analysts noted could bolster institutional interest.The company ended the third quarter of 2024 with $295.28 million in cash and $24.31 million in debt.&nbsp;<a href="https://stocktwits.com/symbol/MNMD">Mind Medicine</a> recently said it raised $250 million last year through two equity financings.The small-cap biotech’s stock has returned about 90% over the past 12 months, though its short interest stands at 13.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company’s lead asset MM120 targets generalized anxiety disorder (GAD) and major depressive disorder (MDD). | Image source: Getty Images

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

MNMD
Mind Medicine Inc - Ordinary Shares (Sub Voting)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MNMD News

MNMD Mind Medicine Inc - Ordinary Shares (Sub Voting)